Ritter J, Escaich S, Chevallier P, Trepo C, Sepetjan M; International Conference on AIDS.
Int Conf AIDS. 1989 Jun 4-9; 5: 444 (abstract no. Th.B.P.169).
Laboratoire de Sante Publique, Lyon, France
OBJECTIVE: To quantify the anti-HIV antibody reactivity on immunoblotting in relation to clinical stage. METHODS: We have studied 450 sera between October 1988 and January 1989, with anti P18/P24 antibody assay (recombinant antigen EIA, Abbott), HIV antigenemia (EIA, Abbott) and scanning densitometry on immunoblotting (Biorad). The same pool of sera was used in each immunoblotting assay as external standard. Results are expressed in percentage of external standard reactivity. RESULTS: Antiglycoprotein antibodies (GP 160 and GP41) and anti POL gene products antibodies (P66 and P32) variations did not correlate with any clinical feature (Stages II, III, IVA and IVCI/IVD from the CDC classification). Anti core protein antibodies exhibit a moderate (P18 and P55) or a high (P24 and P40) correlation with clinical stage. Mean anti P24 reactivity was 22% in AIDS, 31% in ARC and 54% in asymptomatic patients. CONCLUSION: We confirm the decrease of anti core protein antibodies reactivity with disease progression. A retrospective and prospective study will confirm the prognostic interest of this method compared with other markers: HIV antigenemia, CD4+ lymphocyte numeration.
Publication Types:
Keywords:
- AIDS-Related Complex
- Acquired Immunodeficiency Syndrome
- CD4-Positive T-Lymphocytes
- Gene Products, pol
- HIV
- HIV Antibodies
- HIV Antigens
- HIV Core Protein p24
- HIV Envelope Protein gp120
- HIV Envelope Protein gp41
- HIV Infections
- HIV Seropositivity
- HIV-1
- Humans
- Immunoblotting
- Prospective Studies
- Serologic Tests
- immunology
Other ID:
UI: 102178180
From Meeting Abstracts